Literature DB >> 4611256

Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae.

C C Shepard, L Levy, P Fasal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4611256     DOI: 10.4269/ajtmh.1974.23.1120

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


× No keyword cloud information.
  8 in total

1.  Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients.

Authors:  B Ji; S Sow; E Perani; C Lienhardt; V Diderot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Treating Hansen's disease in developing countries.

Authors:  S S Vasireddi
Journal:  West J Med       Date:  1994-03

Review 3.  Treatment of leprosy in the United States.

Authors:  W R Levis
Journal:  Bull N Y Acad Med       Date:  1984-09

4.  Susceptibility of Mycobacterium leprae to dapsone as a determinant of patient response to acedapsone.

Authors:  L Levy; J H Peters
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

5.  Rifampicin for lepromatous leprosy: nine years' experience.

Authors:  M F Waters; R J Rees; J M Pearson; A B Laing; H S Helmy; R H Gelber
Journal:  Br Med J       Date:  1978-01-21

6.  The penetration of dapsone, rifampicin, isoniazid and pyrazinamide into peripheral nerves.

Authors:  B W Allen; G A Ellard; P T Gammon; R C King; A C McDougall; R J Rees; A G Weddell
Journal:  Br J Pharmacol       Date:  1975-09       Impact factor: 8.739

Review 7.  Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.

Authors:  Malcolm S Duthie; Marivic F Balagon
Journal:  Risk Manag Healthc Policy       Date:  2016-04-27

8.  Nitazoxanide is active against Mycobacterium leprae.

Authors:  Mai Ann Bailey; Hana Na; Malcolm S Duthie; Thomas P Gillis; Ramanuj Lahiri; Tanya Parish
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.